Cisplatin News and Research

RSS

MIT finds alternative to common colorectal cancer drug oxaliplatin

A compound that accumulates in cells more readily than a commonly used colorectal cancer drug may be just as useful in treating colorectal tumors, but with fewer side effects, MIT researchers have found.

17 Jun 2008

Cetuximab and chemotherapy combination proves safe, effective for head and neck cancer patients

Patients treated for locally advanced head and neck cancer may respond better to treatment with the addition of cetuximab to chemotherapy, according to a University of Pittsburgh Cancer Institute (UPCI) phase II study. The results will be presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago as an oral presentation.

2 Jun 2008

Asbestos-induced lung cancer patients do not appear to benefit from chemotherapy

Adding chemotherapy to established methods of symptom management does not appear to enhance the quality of life or survival of patients suffering from an asbestos-induced form of lung cancer called malignant plural mesothelioma (MPM). These are the results of MS01, a large UK and Australian study published in the Lancet, which set out to assess the potential benefits of combining active symptom control (ASC) with chemotherapy.

18 May 2008

Combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer

A clinical trial evaluating the benefit of adding the drug sorafenib to the combination of carboplatin/paclitaxel chemotherapy for lung cancer patients has been stopped based on results from an interim analysis, after an independent data monitoring committee concluded that the study would not meet its primary endpoint of improved overall survival.

26 Apr 2008

Multiple studies demonstrate use of hyperthermia therapy in treating pancreatic cancer

BSD Medical Corporation has began to report highlights from 204 abstracts summarizing presentations at the International Congress on Hyperthermic Oncology (ICHO) conducted this month in Munich, Germany

24 Apr 2008

Cisplatin found to be less effective than standard treatment for patients with anal cancer

When administered before chemoradiation, the common anti-cancer drug cisplatin neither improved disease-free survival nor reduced the number of colostomies needed when compared to the standard treatment for patients with anal canal cancer, according to a study published in the April 23 issue of the JAMA, the Journal of the American Medical Association.

22 Apr 2008

Genentech updates on phase III study of Avastin plus chemo in first-line, advanced, non-squamous, non-small cell lung cancer

Genentech, Inc. has announced an update for the previously reported Roche-sponsored international Phase III clinical study (AVAiL) of Avastin (bevacizumab) in combination with gemcitabine and cisplatin chemotherapy, in patients with advanced, non-squamous, non-small cell lung cancer (NSCLC).

21 Apr 2008

Wild Mediterranean plant provides potential anticancer medicines

A group of scientists from the Department of Organic Chemistry and the Biotechnology Institute of the University of Granada have found out that the plant “Dittirichia viscose”, known as elecampe, can be used to obtain inhibitors of neurogenic vasodilatation, a significant progress in migraine and cancer treatments.

17 Apr 2008

Drugs in the pipeline: new therapies that could change treatment strategies

The investigational drug AZD2171 (cediranib) may help shrink tumors and prolong survival of patients with a relatively common, aggressive type of brain cancer, according to results from a clinical trial conducted by Boston researchers.

16 Apr 2008

Postoperative chemotherapy does not improve survival in gastric cancer patients

The use of combination chemotherapy following surgery did not improve survival in patients with gastric cancer, according to a randomized clinical trial published online March 11 in the Journal of the National Cancer Institute .

12 Mar 2008

Nausea from chemotherapy explained

A new study from the Monell Center increases understanding of the biological mechanisms responsible for the nausea and vomiting that often afflict patients undergoing chemotherapy.

4 Feb 2008

New anticancer drugs may block HSP90-IP6K2 protein interaction involved in cell death

Johns Hopkins researchers have discovered a previously unsuspected mechanism of cell death that may afford a new way to find and develop stronger yet less-harmful anticancer drugs.

23 Jan 2008

Barr receives approval for generic KYTRIL tablets

Barr Pharmaceuticals, Inc. has announced that its subsidiary, Barr Laboratories, Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its generic version of Roche Laboratories Inc.'s KYTRIL (granisetron hydrochloride) Tablets, 1mg (eq to 1 mg base).

3 Jan 2008

Light powered platinum more targeted and powerful than similar cancer treatments

Researchers from the Universities of Warwick, Edinburgh, Dundee and the Czech Republic's Institute of Biophysics have discovered a new light-activated platinum-based compound that is up to 80 times more powerful than other platinum-based anti-cancer drugs and which can use "light activation" to kill cancer cells in much more targeted way than similar treatments.

28 Dec 2007

How does the antitumor drug get to the cell nucleus?

Platinum complexes such as the well-known cisplatin are powerful antitumor medications. They cross the cell membrane and reach the nucleus, where they attach to DNA and stop cell growth. But how does cisplatin get to the nucleus Italian researchers have now proven that a copper transport protein may play a critical role.

5 Nov 2007

Copper transporter plays an unexpected role in the absorption of cisplatin

30 Oct 2007

New treatment option studied for bladder cancer

A chemotherapy regimen for patients with advanced bladder cancer who aren't eligible for standard treatment is under study at the Medical College of Georgia.

29 Oct 2007

Combination targets offer new hope in fight against cancer

While some targeted therapies - drugs developed to attack specific molecules in the critical chemical pathways occurring within cancer cells - work well by themselves, increasingly researchers are finding that they work better when teamed with other targeted and conventional therapies.

24 Oct 2007

Combo therapy flavopiridol and cisplatin shows promise for recurrent ovarian cancer resistant to platinum therapy

Mayo Clinic has reported promising interim results from a Phase II trial of a new combination therapy for patients with recurrent ovarian cancer that is resistant to platinum therapy.